Platelet-derived growth factor receptor/platelet-derived growth factor (PDGFR/PDGF) system is a prognostic and treatment response biomarker with multifarious therapeutic targets in cancers

被引：44

作者：

Appiah-Kubi, Kwaku ^{[1
,3
]}

Wang, Ying ^{[1
]}

Qian, Hai ^{[1
]}

Wu, Min ^{[1
]}

Yao, Xiaoyuan ^{[2
]}

Wu, Yan ^{[1
]}

Chen, Yongchang ^{[1
]}

机构：

[1] Jiangsu Univ, Sch Med, Dept Physiol, Zhenjiang 212013, Jiangsu, Peoples R China

[2] Changchun Med Coll, Basic Med Dept, Changchun 130013, Jilin, Peoples R China

[3] Univ Dev Studies, Dept Appl Biol, Navrongo, Ghana

来源：

TUMOR BIOLOGY | 2016年 / 37卷 / 08期

基金：

中国国家自然科学基金; 中国博士后科学基金;

关键词：

PDGFR/PDGF system; Therapeutic targets; Prognostic marker; Treatment response biomarker; Small molecules; Immunotherapy; Gene therapy; RENAL-CELL CARCINOMA; RECEPTOR-ALPHA EXPRESSION; COPY NUMBER GAIN; PHASE-II TRIAL; IMATINIB MESYLATE; FACTOR PDGF; MONOCLONAL-ANTIBODY; RNA INTERFERENCE; POTENT INHIBITOR; PROSTATE-CANCER;

D O I：

10.1007/s13277-016-5069-z

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Progress in cancer biology has led to an increasing discovery of oncogenic alterations of the platelet-derived growth factor receptors (PDGFRs) in cancers. In addition, their overexpression in numerous cancers invariably makes PDGFRs and platelet-derived growth factors (PDGFs) prognostic and treatment markers in some cancers. The oncologic alterations of the PDGFR/PDGF system affect the extracellular, transmembrane and tyrosine kinase domains as well as the juxtamembrane segment of the receptor. The receptor is also involved in fusions with intracellular proteins and receptor tyrosine kinase. These discoveries undoubtedly make the system an attractive oncologic therapeutic target. This review covers elementary biology of PDGFR/PDGF system and its role as a prognostic and treatment marker in cancers. In addition, the multifarious therapeutic targets of PDGFR/PDGF system are discussed. Great potential exists in the role of PDGFR/PDGF system as a prognostic and treatment marker and for further exploration of its multifarious therapeutic targets in safe and efficacious management of cancer treatments.

引用

页码：10053 / 10066

页数：14

共 138 条

[121] New insights into the mechanisms of hematopoietic cell transformation by activated receptor tyrosine kinases [J].

Toffalini, Federica ;

Demoulin, Jean-Baptiste .

BLOOD, 2010, 116 (14) :2429-2437

[122] Aptamers-based assays for diagnostics, environmental and food analysis [J].

Tombelli, Sara ;

Minunni, Maria ;

Mascini, Marco .

BIOMOLECULAR ENGINEERING, 2007, 24 (02) :191-200

[123] Role of PDGF in fibrotic diseases and systemic sclerosis [J].

Trojanowska, M. .

RHEUMATOLOGY, 2008, 47 :V2-V4

[124] Elevated PDGFRB gene copy number gain is prognostic for improved survival outcomes in resected malignant pleural mesothelioma [J].

Tsao, Anne S. ;

Harun, Nusrat ;

Fujimoto, Junya ;

Devito, Vikki ;

Lee, J. Jack ;

Kuhn, Elisabetta ;

Mehran, Reza ;

Rice, David ;

Moran, Cesar ;

Hong, Waun Ki ;

Shen, Li ;

Suraokar, Milind ;

Wistuba, Ignacio .

ANNALS OF DIAGNOSTIC PATHOLOGY, 2014, 18 (03) :140-145

[125] Immunohistochemical Overexpression of Platelet-Derived Growth Factor Receptor-Beta (PDGFR-β) is Associated With PDGFRB Gene Copy Number Gain in Sarcomatoid Non-Small-Cell Lung Cancer [J].

Tsao, Anne S. ;

Wei, Wei ;

Kuhn, Elisabetta ;

Spencer, Loreto ;

Solis, Luisa M. ;

Suraokar, Milind ;

Lee, J. Jack ;

Hong, Waun Ki ;

Wistuba, Ignacio I. .

CLINICAL LUNG CANCER, 2011, 12 (06) :369-374

[126] Vascular endothelial growth factors and receptors: Anti-angiogenic therapy in the treatment of cancer [J].

Tugues, Sonia ;

Koch, Sina ;

Gualandi, Laura ;

Li, Xiujuan ;

Claesson-Welsh, Lena .

MOLECULAR ASPECTS OF MEDICINE, 2011, 32 (02) :88-111

[127] RNAi screen for rapid therapeutic target identification in leukemia patients [J].

Tyner, Jeffrey W. ;

Deininger, Michael W. ;

Loriaux, Marc M. ;

Chang, Bill H. ;

Gotlib, Jason R. ;

Willis, Stephanie G. ;

Erickson, Heidi ;

Kovacsovics, Tibor ;

O'Hare, Thomas ;

Heinrich, Michael C. ;

Druker, Brian J. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (21) :8695-8700

[128] Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial [J].

van der Graaf, Winette T. A. ;

Blay, Jean-Yves ;

Chawla, Sant P. ;

Kim, Dong-Wan ;

Binh Bui-Nguyen ;

Casali, Paolo G. ;

Schoffski, Patrick ;

Aglietta, Massimo ;

Staddon, Arthur P. ;

Beppu, Yasuo ;

Le Cesne, Axel ;

Gelderblom, Hans ;

Judson, Ian R. ;

Araki, Nobuhito ;

Ouali, Monia ;

Marreaud, Sandrine ;

Hodge, Rachel ;

Dewji, Mohammed R. ;

Coens, Corneel ;

Demetri, George D. ;

Fletcher, Christopher D. ;

Tos, Angelo Paolo Dei ;

Hohenberger, Peter .

LANCET, 2012, 379 (9829) :1879-1886

[129] Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: A study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG) [J].

Van Glabbeke, Martine ;

Verweij, Jaap ;

Casali, Paolo G. ;

Simes, John ;

Le Cesne, Axel ;

Reichardt, Peter ;

Issels, Rolf ;

Judson, Ian R. ;

van Oosterom, Allan T. ;

Blay, Jean-Yves .

EUROPEAN JOURNAL OF CANCER, 2006, 42 (14) :2277-2285

[130] Towards a targeted multi-drug delivery approach to improve therapeutic efficacy in breast cancer [J].

Wang, Bin ;

Rosano, Jenna M. ;

Cheheltani, Rabe'e ;

Achary, Mohan P. ;

Kiani, Mohammad F. .

EXPERT OPINION ON DRUG DELIVERY, 2010, 7 (10) :1159-1173

← 5 6 7 8 9 10 11 12 13 14 →